KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deferred Tax Liability (2016 - 2026)

Astrazeneca has reported Non-Current Deferred Tax Liability over the past 17 years, most recently at -$3.5 billion for Q1 2026.

  • For Q1 2026, Non-Current Deferred Tax Liability rose 2.31% year-over-year to -$3.5 billion; the TTM value through Mar 2026 reached -$3.5 billion, up 2.31%, while the annual FY2025 figure was -$3.5 billion, 205.9% down from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 was -$3.5 billion at Astrazeneca, up from -$3.5 billion in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $3.3 billion in Q4 2024 and troughed at -$5.6 billion in Q1 2022.
  • A 5-year average of -$2.4 billion and a median of -$3.5 billion in 2026 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: surged 50.32% in 2023 and later tumbled 205.9% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $2.9 billion in 2022, then decreased by 3.4% to $2.8 billion in 2023, then grew by 16.21% to $3.3 billion in 2024, then tumbled by 205.9% to -$3.5 billion in 2025, then rose by 0.83% to -$3.5 billion in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for AZN at -$3.5 billion in Q1 2026, -$3.5 billion in Q4 2025, and -$3.6 billion in Q3 2025.